News Pfizer ducks out of Sangamo haemophilia A alliance Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.
News Sanofi takes SK Bio-partnered pneumococcal shot into phase 3 Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.
News MSD makes its obesity move with $2bn Hansoh deal MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.
News Genmab expands its pipeline with $630m Scancell deal Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
News Gilead looks beyond Trodelvy with Tubulis alliance Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
News Orexo exits depression DTx alliance with GAIA Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
News Patient organisations 'too influenced by corporate funders' Researchers have called for action to safeguard the independence of patient advocacy organisations as they increasingly rely on pharma funding.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.